Market Cap: $108.8B
SA
Sanofi
SNY
NASDAQ (NASDAQ Global Select)USD
Market Cap: $108.8B
Sanofi (Ticker: SNY) partners with the Department of Health in Abu Dhabi to enhance global vaccine innovation through a new initiative. They sign a Memorandum of Understanding (MoU) to establish a Vac…
On June 23, 2026, Sanofi (Ticker: SNY) and the Department of Health – Abu Dhabi (DoH) formalize their partnership to drive vaccine innovation through the signing of a Memorandum of Understanding. This…
Sanofi (Ticker: SNY) takes a substantial step in pediatric healthcare by expanding the use of its therapy to treat younger patients, reinforcing its dedication to addressing unmet medical needs. This…
Sanofi (Ticker: SNY) expands the use of its therapy for pediatric patients, demonstrating its commitment to meeting the medical needs of younger populations. This significant decision is backed by pos…
Sanofi (Ticker: SNY) announces its decision to discontinue the Phase 3 MOBILIZE study, which evaluated riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who did not…
Sanofi's Breakthrough in COPD Treatment: Tozorakimab's Revolutionary Approach Sanofi stands at the forefront of respiratory disease management with its latest innovation, Tozorakimab, a monoclonal ant…
Sanofi Expands Immunology Portfolio Through Partnership with Kali Therapeutics Sanofi enhances its foothold in immunology with a licensing agreement for KT501, an innovative tri-specific T-cell engage…
Federal Court Critiques U.S. Vaccine Advisory Practices: Implications for Public Health Policy In a significant legal development, a federal court raises concerns regarding recent actions by the U.S.…
Legal Accountability in Public Health Policies: A Turning Point for Vaccine Governance Recent rulings by a federal court spotlight significant concerns about the U.S. government's handling of vaccinat…
Strategic Positioning in Biotech: AstraZeneca’s Pursuit of Abivax In recent developments in the biotech sector, AstraZeneca Plc emerges as a leading candidate for the acquisition of French biotechnolo…
AstraZeneca's Strategic Acquisition Moves Highlight Industry Dynamics In a significant development within the biotechnology sector, British drugmaker AstraZeneca Plc emerges as a leading candidate for…
AstraZeneca Targets Abivax: A Strategic Move in Biotech Recent developments in the biotech industry spotlight AstraZeneca Plc as it emerges as a leading contender for the acquisition of French biotech…
A Breakthrough Therapy: AYVAKIT® Enhances Quality of Life for Patients with Indolent Systemic Mastocytosis Blueprint Medicines, a subsidiary of Sanofi, showcases groundbreaking advancements in the tre…
### Sanofi’s Shifting Investor Sentiment Marks a Positive Trend Sanofi SA is witnessing a significant shift in investor sentiment as the company reports a 5.13% decline in short interest within the la…
Sanofi’s AYVAKIT® Therapy Demonstrates Efficacy for Systemic Mastocytosis Patients Sanofi’s Blueprint Medicines recently presents compelling data from its four-year PIONEER clinical study on AYVAKIT®…
Sanofi's Position Amidst Competitive Pressures in Biopharmaceuticals In the competitive landscape of biopharmaceuticals, Sanofi remains acutely aware of the challenges that companies like Regeneron Ph…
Navigating Competitive Waters: Regeneron's Struggles Amidst Industry Challenges Regeneron Pharmaceuticals finds itself at a critical juncture as it faces significant challenges in maintaining its mark…
Pharma pivoting to speed oncology antibodies and simplify delivery Regulatory accelerants and subcutaneous delivery are reshaping how big drugmakers advance antibody therapies, a shift that is closely…
Sanofi names Manuela Buxo to lead Specialty Care and Dupixent strategy Sanofi appoints Manuela Buxo as head of its Specialty Care Global Business Unit, effective March 1, 2026, with Buxo joining the c…
Sanofi names Manuela Buxo to lead Specialty Care global push Building on Dupixent momentum: continuity at the top of Specialty Care Sanofi appoints Manuela Buxo as Head of Specialty Care, effective Ma…
Sanofi signs on to TrumpRx push to sell medicines directly to consumers Sanofi is among major drugmakers that the White House says commit to the Trump administration’s new TrumpRx programme, a direct-…
White House unveils TrumpRx with Sanofi among signatories Sanofi is among a group of drugmakers that the White House says commit to steep discounts under the administration’s new TrumpRx program, whic…
White House launches TrumpRx, naming major drugmakers including Sanofi The White House is unveiling a new direct-to-consumer prescription drug initiative called TrumpRx that several major pharmaceutic…
Sanofi's Commitment to Innovation Amid Global Challenges Sanofi continues to solidify its position in the biopharmaceutical industry, focusing on innovation in response to evolving healthcare demands.…
Sanofi's Strategic Focus Amid Global Economic Uncertainty In the face of significant geopolitical tensions and economic volatility, Sanofi navigates a complex landscape that impacts its operations and…
Sanofi Expands Partnership with CytoReason to Enhance Drug Development Efficiency Sanofi extends its collaboration with CytoReason, an innovative AI-powered computational disease modeling firm based i…
Regeneron Pharmaceuticals: A Potential Turning Point in Drug Development Recent developments in Regeneron Pharmaceuticals Inc.'s operations signal a promising outlook for the biotechnology company, de…
Sanofi's Strategic Position in an Evolving Biotechnology Landscape Sanofi is currently navigating a pivotal moment in the biotechnology sector, marked by increasing competition and innovation. As the…
Sanofi and Earendil Labs Forge Strategic Alliance to Combat Autoimmune Diseases Sanofi enters a transformative partnership with Earendil Labs, a leading AI-driven biotech firm, to enhance the developm…
Sanofi and Earendil Labs Forge Alliance to Tackle Autoimmune Diseases Sanofi, a leading global biopharmaceutical company, partners with Earendil Labs, an innovative AI-driven biotech firm, to enhance…
Sanofi's Position in the Biopharmaceutical Landscape: Emphasizing Innovation and Leadership Sanofi continues to solidify its standing as a pivotal player in the biopharmaceutical industry, where innov…
Judicial Ruling Impacts 340B Drug Pricing Program: Implications for Healthcare Access A recent federal judge's temporary injunction against the U.S. administration's 340B Rebate Model Pilot Program ra…
Sanofi Expands Biotech Portfolio with Dynavax Acquisition Sanofi SA announces a definitive agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, amounting to an equity va…
Sanofi's Strategic Move to Enhance Immunotherapy Portfolio through Dynavax Acquisition Sanofi SA has recently announced its decision to acquire Dynavax Technologies Corporation for $15.50 per share in…
Roche's Pricing Concerns Highlight Global Pharmaceutical Challenges Thomas Schinecker, CEO of Roche Holding AG, articulates significant concerns regarding the implications of U.S. government agreement…
Transforming Drug Affordability: Sanofi's Role in a New Healthcare Landscape In a landmark move, the U.S. government collaborates with nine major pharmaceutical companies to address the pressing issue…
Sanofi Partners with ADEL, Inc. to Develop Innovative Alzheimer’s Therapy In a significant development in the biopharmaceutical landscape, Sanofi has secured an exclusive worldwide license agreement w…
Sanofi Advances in Immunology with Innovative Treatment Approaches Sanofi, a global leader in healthcare, positions itself at the forefront of immunology with its latest advancements in treatment meth…
Sanofi's Pioneering Role in Advancing AI-Driven Drug Development In a rapidly evolving pharmaceutical landscape, Sanofi stands out for its commitment to integrating artificial intelligence (AI) into d…
Sanofi Expands Treatment Options for Rare Blood Disorders in China Sanofi SA secures a significant milestone in its therapeutic offerings with the recent approval from China's National Medical Product…
Sanofi Expands Hematology Portfolio with NMPA Approvals in China Sanofi SA receives a notable boost in its hematology treatment offerings following the National Medical Products Administration (NMPA)…
Kymera Therapeutics Advances Breakthrough Treatment for Atopic Dermatitis Kymera Therapeutics, Inc. recently unveils promising clinical results from its BroADen Phase 1b trial of KT-621, an oral STAT6…
Kymera Therapeutics Advances Treatment for Atopic Dermatitis Kymera Therapeutics, Inc. recently announces promising results from its BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader…
Sanofi Eyes Competitive Landscape Amid Regeneron Developments Sanofi, a key player in the global pharmaceutical industry, is currently navigating a challenging market landscape marked by shifting inve…
Sanofi's Strategic Positioning Amidst Industry Challenges In the current landscape of the pharmaceutical industry, Sanofi remains focused on navigating various market challenges while striving for gro…
Sanofi's Strategic Focus Amid Industry Uncertainty As the pharmaceutical landscape faces increasing scrutiny and a shift in investor sentiment, Sanofi remains strategically positioned to navigate thes…
Sanofi Under Investigation: Tax Probe Reflects Growing Regulatory Scrutiny in Pharma Sanofi SA faces a significant challenge as tax investigators conduct an unannounced search of its Paris headquarter…
DarioHealth's Study Highlights Efficacy of Digital Health Solutions for Diabetes Management DarioHealth Corp. recently publishes a pivotal study in the Journal of Medical Internet Research, demonstrat…
Sanofi Partners with DarioHealth to Assess Digital Diabetes Management A recent study published in the Journal of Medical Internet Research (JMIR) showcases a significant collaboration between Sanofi…
Legal Action Highlights Accountability Gaps in Pharmaceutical Industry In a significant legal development, Texas Attorney General Ken Paxton leads a lawsuit against Bristol-Myers Squibb Company and se…